22/12/2025
On 16 December 2025, PhAMA was pleased to engage with Deputy Director General of Health, Dr Azuana Ramli, and the team from the Pharmaceutical Services Programme (PSP), Ministry of Health Malaysia, in a constructive dialogue focused on advancing patient access to quality, safe, and effective medicines.
Dr Azuana reaffirmed the Ministry’s strong commitment to public–private partnerships and highlighted ongoing efforts to enhance the MOH Medicine Formulary (Blue Book).
The session also underscored encouraging progress, including an increase in the number of new medicines listed in the MOH Formulary, as well as the importance of high-quality dossier submissions to support efficient and evidence-based decision-making.
Capacity-building initiatives - such as the Insights into New Guidelines workshop co-organised by PSP and PhAMA in November 2024 - were recognised as important enablers in strengthening both industry submissions and evaluator capabilities.
Looking ahead, discussions focused on expanding collaboration in areas such as HTA capability building, Pharmacoeconomic guidelines, and the use of local RWE, with a shared emphasis on practical solutions, technical alignment, and measurable outcomes.
PhAMA extends our appreciation to Dr Azuana and the Pharmaceutical Services Programme team for their openness to dialogue and continued commitment. We look forward to building on this partnership to further strengthen evidence-based decision-making and enhance patient access to innovative medicines in Malaysia.
